πŸ‡ΊπŸ‡Έ FDA
Patent

US 10934337

Anti-BCMA chimeric antigen receptors

granted A61KA61K2039/505A61K2239/46

Quick answer

US patent 10934337 (Anti-BCMA chimeric antigen receptors) held by Cartesian Therapeutics, Inc. expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cartesian Therapeutics, Inc.
Grant date
Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K2239/46, A61K38/00, A61K39/3955